Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + orelabrutinib in relapsed or refractory non-Hodgkin lymphoma (China, phase IIa)
CTR20231546Phase 2Active
- Sponsor
- Incyte
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab, lenalidomide, orelabrutinib in mature B-cell lymphoma, sponsored by Incyte. Started May 2023; status: active.
02
Drugs
tafasitamablenalidomideorelabrutinib
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20231546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231546.